Обзорная статья

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

Federica MigliettaDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ItalyMichele BottossoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ItalyGaia GriguoloDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, ItalyMaria Vittoria DieciDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, ItalyValentina GuarneriDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic address: [email protected]

2022en

ABI

Аннотация

In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.

Перевод пока недоступен

Идентификаторы

DOI: 10.1016/j.esmoop.2022.100409

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar